



PROACTIVEINVESTORS interview with CEO, Dr Sarah Howell re the dosing of Arecor's first patient in its Phase I clinical trial of its rapid-acting insulin product candidate, AT247, for the improved treatment of diabetes.



Areacor, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, announces the initiation of its AT247 Phase I clinical trial and an important next step in the Company's strategy to develop even faster acting insulins targeted at improving treatment and health outcomes for people living with Type 1 diabetes.

Watch the interview here:

<https://www.proactiveinvestors.co.uk/companies/stocktube/13235/arecor-doses-first-patient-in-phase-i-trial-for-ultra-rapid-acting-insulin-product-13235.html>